Is reoperation for gastrinoma excision indicated in Zollinger-Ellison syndrome?

• Published in: Surgery 1996-12, Vol.120 (6), p.1055-1063
• Main Authors: Jaskowiak, Nora T., Fraker, Douglas L., Alexander, H. Richard, Norton, Jeffrey A., Doppman, John L., Jensen, Robert T.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Female; Gastrinoma - surgery; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms - surgery; Postoperative Complications; Reoperation; Zollinger-Ellison Syndrome - surgery
• ISSN: 0039-6060; 1532-7361
• DOI: 10.1016/S0039-6060(96)80055-9

background. Surgical excision of gastrinomas in patients with Zollinger-Ellison syndrome (ZES) decreases the incidence of hepatic metastases, but long-term biochemical cures are achieved in fewer than 30% of cases. A growing number of patients have persistent or recurrent disease after initial operation. The effect of reoperation in these patients has not been previously reported. Methods. From December 1982 to August 1995, 120 patients with ZES underwent operation for gastrinoma resection. Seventy-eight patients had recurrent or persistent ZES after operation; 17 patients underwent 18 reoperations. After initial operation all patients underwent yearly functional and imaging studies. If a tumor was unequivocally imaged, reexploration was done. Results. Five patients, all with sporadic disease, were disease free after operation, with a median follow-up of 28 months. Tumor was found in all 18 reoperations and resected in 17. In patients with continuing disease-free intervals, locations of gastrinomas included pancreatic head lymph nodes (three), liver metastasis (one), and pancreatic tail lymph node (one). There were no deaths in the cured group; two patients in the group with persistent disease have died (median follow-up, 34 months). Conclusions. Reoperation for gastrinoma excision resulted in elimination of disease in 30% of patients and should be considered for patients with imageable disease.